12,372 trials
Herpes Zoster
Primary: Vaccine Response Rates (VRR) for Anti-glycoprotein E (Anti-gE) Antibody Concentrations — 80.4; 0.8 Percentage
Cystinosis
Primary: Average Difference Between Morning and Non-Morning Log White Blood Cell (WBC) Cystine Values — -0.229; 0.080 log [nmol ½ cystine/mg protein] — p=0.0048
Herpes Zoster · Herpes Zoster Vaccine
Primary: Number of Subjects With Anti-gE Antibody Concentrations Equal to or Above the Cut-off Value — 210; 210; 202 Subjects
Bronchiectasis
Primary: Time to First Exacerbation Event Within 48 Weeks — 336; NA; 186 Days — p=0.0650
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) Per Independent Radiologic Review. — 2.6; 2.5 Months — p=0.195
Osteoarthritis
Primary: Allograft Stability — 0
Colon Cancer · Colorectal Carcinoma · Colon Cleansing
Primary: Number of Patients With Successful Bowel Cleansing (Overall Colon) — 238; 235; 42; 41 Participants — p=0.528
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c — -2.01; -2.02 percentage — p=0.012
Alzheimer's Disease
Primary: Change From Baseline (W0) in Mean ADAS-Cog Total Score at W24 as a Function of APOE e4 Status in Apolipoprotein epsilon4 (APOE e4) Negative Cohort — 1.6; -0.2; 0.6; 0.9…
Mucopolysaccharidosis IV A · Morquio A Syndrome · MPS IVA
Primary: Change From Baseline in 6-minute Walk (6MW) Test - ITT — 219.7; 207.2; 205.7; 203.9 meters
Chronic Idiopathic Constipation
Primary: Percentage of 12-Week CSBM Overall Responders — 4.7; 13.4; 95.3; 86.6 percentage of participants — p=< 0.0001
Heterozygous Familial Hypercholesterolemia
Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -0.3; -54.2 percent change — p=<0.001
Ulcerative Colitis
Primary: Percentage of Participants In Remission at Week 52 — 34.3; 40.6; 11.1 percentage of participants — p=<0.0001
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Change From Baseline in Mean Systolic Blood Pressure at Final Assessment — 107.5; 113.5; 0.9; 0.3 millimeter of mercury (mmHg)
Giant Cell Arteritis
Primary: Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 26 Weeks Prednisone Taper) — 56.0; 53.1; 14.0…